TrialJournal for immunotherapy of cancer2021

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).

Yunpeng Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.